Tonix Pharmaceuticals (TNXP, Financial) recently showcased encouraging preclinical results for its novel vaccine, TNX-801, at the World Vaccine Congress in Washington, D.C. The presentation focused on the vaccine's ability to offer protection against mpox and rabbitpox with just a single dose, while also being well tolerated in animals, including those with compromised immune systems.
Research indicates that TNX-801 confers durable immunity, protecting animals for up to six months from a lethal rabbitpox challenge and shields immunocompromised animals from a deadly monkeypox clade IIa virus attack. Previous studies have also demonstrated the vaccine's effectiveness in preventing severe disease and lesion formation in animals after a single dose.
The ongoing mpox outbreaks, including those classified as Public Health Emergencies of International Concern by the World Health Organization in 2022 and 2024, underscore the urgent need for effective vaccine solutions. TNX-801, which is a minimally replicative, live-virus vaccine derived from synthesized horsepox, aligns with the WHO's target product profile for new vaccines, emphasizing single-dose, durable protection and ease of use without specialized equipment.
Tonix Pharmaceuticals is optimistic about TNX-801's potential impact in managing and preventing future mpox outbreaks, particularly given its promising safety profile and immunogenicity compared to traditional vaccinia vaccines. The company intends to continue exploring TNX-801's capabilities in hopes of contributing significantly to global public health efforts.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Tonix Pharmaceuticals Holding Corp (TNXP, Financial) is $406.67 with a high estimate of $1,100.00 and a low estimate of $50.00. The average target implies an upside of 2,299.21% from the current price of $16.95. More detailed estimate data can be found on the Tonix Pharmaceuticals Holding Corp (TNXP) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Tonix Pharmaceuticals Holding Corp's (TNXP, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
